FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008291230> ?p ?o ?g. }

• W2008291230 endingPage "278" @default.
• W2008291230 startingPage "273" @default.
• W2008291230 abstract "Abstract EM‐652 exerts pure antiestrogenic activity in the mammary gland and endometrium, while tamoxifen, the antiestrogen most widely used for the treatment of breast cancer, exerts mixed antiestrogenic–estrogenic activity in these tissues. Our objective was to compare the agonistic and antagonistic effects of EM‐652 with tamoxifen and 5 other antiestrogens on the growth of ZR‐75‐1 human breast xenografts in ovariectomized nude mice. During the 23 weeks of treatment at a daily oral dose of 50 μg, EM‐652 was the only compound that decreased tumor size relative to pretreatment values, whereas the 6 other antiestrogens only decreased to various extents the progression rate stimulated by estrone. Under estrone stimulation, all groups of animals had more than 60% of their tumors in the progression category except for the EM‐652–treated group, where only 7% of the tumors progressed. In the absence of estrone stimulation, progression was seen in 60%, 33%, 21% and 12% of tumors in the tamoxifen‐, idoxifene‐, toremifene‐ and raloxifene‐treated groups, respectively, while only 4% of tumors progressed in the EM‐652–treated group. The agonistic and antagonistic actions of each antiestrogen were also measured on endometrial epithelial cell thickness. Our present findings indicate that EM‐652, in addition to being the most potent antiestrogen on human breast tumor growth, has no agonistic effect in breast and endometrial tissues. Since previous data have shown benefits of EM‐652 on bone density and lipid profile, this compound could be an ideal candidate for chemoprevention of breast and uterine cancers, while protecting against osteoporosis and cardiovascular disease. © 2002 Wiley‐Liss, Inc." @default.
• W2008291230 created "2016-06-24" @default.
• W2008291230 creator A5003484727 @default.
• W2008291230 creator A5005889903 @default.
• W2008291230 creator A5022492237 @default.
• W2008291230 creator A5040744081 @default.
• W2008291230 creator A5065560889 @default.
• W2008291230 creator A5088596716 @default.
• W2008291230 date "2002-04-11" @default.
• W2008291230 modified "2023-10-17" @default.
• W2008291230 title "Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice" @default.
• W2008291230 cites W137490686 @default.
• W2008291230 cites W1562190372 @default.
• W2008291230 cites W1642413975 @default.
• W2008291230 cites W1832761646 @default.
• W2008291230 cites W1918705397 @default.
• W2008291230 cites W1981306061 @default.
• W2008291230 cites W1994610843 @default.
• W2008291230 cites W2004271411 @default.
• W2008291230 cites W2007007521 @default.
• W2008291230 cites W2008039212 @default.
• W2008291230 cites W2018157403 @default.
• W2008291230 cites W2023320733 @default.
• W2008291230 cites W2032104148 @default.
• W2008291230 cites W2034938609 @default.
• W2008291230 cites W2048501545 @default.
• W2008291230 cites W2048827709 @default.
• W2008291230 cites W2049033233 @default.
• W2008291230 cites W2059972525 @default.
• W2008291230 cites W2069783639 @default.
• W2008291230 cites W2073169219 @default.
• W2008291230 cites W2073621968 @default.
• W2008291230 cites W2079500170 @default.
• W2008291230 cites W2086056904 @default.
• W2008291230 cites W2110997369 @default.
• W2008291230 cites W2141647078 @default.
• W2008291230 cites W2152485630 @default.
• W2008291230 cites W2157113084 @default.
• W2008291230 cites W2161174332 @default.
• W2008291230 cites W2161550802 @default.
• W2008291230 cites W2172185687 @default.
• W2008291230 cites W4235648025 @default.
• W2008291230 cites W4254096897 @default.
• W2008291230 cites W5088785 @default.
• W2008291230 doi "https://doi.org/10.1002/ijc.10302" @default.
• W2008291230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11979444" @default.
• W2008291230 hasPublicationYear "2002" @default.
• W2008291230 type Work @default.
• W2008291230 sameAs 2008291230 @default.
• W2008291230 citedByCount "34" @default.
• W2008291230 countsByYear W20082912302012 @default.
• W2008291230 countsByYear W20082912302014 @default.
• W2008291230 countsByYear W20082912302015 @default.
• W2008291230 countsByYear W20082912302017 @default.
• W2008291230 countsByYear W20082912302018 @default.
• W2008291230 countsByYear W20082912302020 @default.
• W2008291230 countsByYear W20082912302022 @default.
• W2008291230 crossrefType "journal-article" @default.
• W2008291230 hasAuthorship W2008291230A5003484727 @default.
• W2008291230 hasAuthorship W2008291230A5005889903 @default.
• W2008291230 hasAuthorship W2008291230A5022492237 @default.
• W2008291230 hasAuthorship W2008291230A5040744081 @default.
• W2008291230 hasAuthorship W2008291230A5065560889 @default.
• W2008291230 hasAuthorship W2008291230A5088596716 @default.
• W2008291230 hasConcept C121608353 @default.
• W2008291230 hasConcept C126322002 @default.
• W2008291230 hasConcept C134018914 @default.
• W2008291230 hasConcept C2776067312 @default.
• W2008291230 hasConcept C2777088508 @default.
• W2008291230 hasConcept C2777164284 @default.
• W2008291230 hasConcept C2777176818 @default.
• W2008291230 hasConcept C2777637070 @default.
• W2008291230 hasConcept C2777944059 @default.
• W2008291230 hasConcept C2778001805 @default.
• W2008291230 hasConcept C2778656385 @default.
• W2008291230 hasConcept C2779742232 @default.
• W2008291230 hasConcept C2779889926 @default.
• W2008291230 hasConcept C530470458 @default.
• W2008291230 hasConcept C71924100 @default.
• W2008291230 hasConcept C8264082 @default.
• W2008291230 hasConceptScore W2008291230C121608353 @default.
• W2008291230 hasConceptScore W2008291230C126322002 @default.
• W2008291230 hasConceptScore W2008291230C134018914 @default.
• W2008291230 hasConceptScore W2008291230C2776067312 @default.
• W2008291230 hasConceptScore W2008291230C2777088508 @default.
• W2008291230 hasConceptScore W2008291230C2777164284 @default.
• W2008291230 hasConceptScore W2008291230C2777176818 @default.
• W2008291230 hasConceptScore W2008291230C2777637070 @default.
• W2008291230 hasConceptScore W2008291230C2777944059 @default.
• W2008291230 hasConceptScore W2008291230C2778001805 @default.
• W2008291230 hasConceptScore W2008291230C2778656385 @default.
• W2008291230 hasConceptScore W2008291230C2779742232 @default.
• W2008291230 hasConceptScore W2008291230C2779889926 @default.
• W2008291230 hasConceptScore W2008291230C530470458 @default.
• W2008291230 hasConceptScore W2008291230C71924100 @default.
• W2008291230 hasConceptScore W2008291230C8264082 @default.
• W2008291230 hasIssue "2" @default.
• W2008291230 hasLocation W20082912301 @default.

• next